PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics

PTC Therapeutics, Inc. (PTCT): $22.41

0.25 (-1.10%)

POWR Rating

Component Grades








Add PTCT to Watchlist
Sign Up

Industry: Biotech




#86 of 356

in industry

PTCT Price/Volume Stats

Current price $22.41 52-week high $59.84
Prev. close $22.66 52-week low $22.03
Day low $22.22 Volume 767,700
Day high $23.37 Avg. volume 839,601
50-day MA $36.39 Dividend yield N/A
200-day MA $43.52 Market Cap 1.69B

PTCT Stock Price Chart Interactive Chart >


  • PTCT scores best on the Value dimension, with a Value rank ahead of 78.64% of US stocks.
  • PTCT's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • PTCT ranks lowest in Sentiment; there it ranks in the 0th percentile.

PTCT Stock Summary

  • PTC THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.93% of US listed stocks.
  • Of note is the ratio of PTC THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 9.59% of US stocks have a lower such ratio.
  • PTCT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.87% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PTC THERAPEUTICS INC are TSHA, STX, PZG, ABSI, and AUMN.
  • PTCT's SEC filings can be seen here. And to visit PTC THERAPEUTICS INC's official web site, go to

PTCT Valuation Summary

  • In comparison to the median Healthcare stock, PTCT's EV/EBIT ratio is 133.62% lower, now standing at -3.9.
  • Over the past 125 months, PTCT's price/earnings ratio has gone down 5.6.

Below are key valuation metrics over time for PTCT.

Stock Date P/S P/B P/E EV/EBIT
PTCT 2023-09-22 2.2 -3.1 -2.9 -3.9
PTCT 2023-09-21 2.3 -3.2 -3.0 -4.0
PTCT 2023-09-20 2.3 -3.3 -3.1 -4.1
PTCT 2023-09-19 2.4 -3.3 -3.1 -4.1
PTCT 2023-09-18 2.2 -3.2 -3.0 -4.0
PTCT 2023-09-15 2.4 -3.4 -3.2 -4.2

PTCT Growth Metrics

    Its 2 year revenue growth rate is now at 77.02%.
  • The 3 year cash and equivalents growth rate now stands at -28.32%.
  • Its 4 year net cashflow from operations growth rate is now at -51.61%.
Over the past 49 months, PTCT's revenue has gone up $440,191,000.

The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 696.617 -259.531 -531.393
2022-06-30 618.233 -272.676 -555.702
2022-03-31 569.383 -248.579 -521.985
2021-12-31 538.593 -251.332 -523.901
2021-09-30 492.225 -246.858 -454.99
2021-06-30 471.886 -169.009 -391.058

PTCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTCT has a Quality Grade of C, ranking ahead of 45.84% of graded US stocks.
  • PTCT's asset turnover comes in at 0.235 -- ranking 183rd of 682 Pharmaceutical Products stocks.
  • NMTR, ZIOP, and ATXS are the stocks whose asset turnover ratios are most correlated with PTCT.

The table below shows PTCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.235 0.943 -0.271
2021-06-30 0.221 0.945 -0.205
2021-03-31 0.216 0.944 -0.305
2020-12-31 0.205 0.950 -0.360
2020-09-30 0.210 0.951 -0.473
2020-06-30 0.198 0.949 -0.648

PTCT Price Target

For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.58 Average Broker Recommendation 1.77 (Moderate Buy)

PTC Therapeutics, Inc. (PTCT) Company Bio

PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.

PTCT Latest News Stream

Event/Time News Detail
Loading, please wait...

PTCT Latest Social Stream

Loading social stream, please wait...

View Full PTCT Social Stream

Latest PTCT News From Around the Web

Below are the latest news stories about PTC THERAPEUTICS INC that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics (PTCT) Lost 16% in Q2

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […]

Yahoo | September 25, 2023

PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | September 20, 2023

Analysts on Wall Street Lower Ratings for These 10 Stocks

In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks. Stock markets displayed volatility as traders prepared for the possibility of a hawkish message from major central banks […]

Yahoo | September 19, 2023

Biotech Crashes 30% After European Regulators Yank Approval For Muscle Disease Drug

European regulators voted against fully approving a muscular dystrophy treatment from PTC Therapeutics, and PTC stock crashed Friday.

Yahoo | September 15, 2023

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization. PTC plans to submit a reques

Yahoo | September 15, 2023

Read More 'PTCT' Stories Here

PTCT Price Returns

1-mo -43.27%
3-mo -44.90%
6-mo -52.75%
1-year -55.36%
3-year -52.06%
5-year -51.82%
YTD -41.29%
2022 -4.17%
2021 -34.74%
2020 27.07%
2019 39.95%
2018 105.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!